Left Ventricular Hypertrophy clinical trials at UCSD
2 research studies open to eligible people
Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
open to eligible males ages 8 years and up
This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.
La Jolla, California and other locations
Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
open to eligible people ages 40-84
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
La Jolla, California and other locations
Our lead scientists for Left Ventricular Hypertrophy research studies include Barry Greenberg, MD.
Last updated: